These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32551603)

  • 1. Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach.
    Lorthiois E; Roache J; Barnes-Seeman D; Altmann E; Hassiepen U; Turner G; Duvadie R; Hornak V; Karki RG; Schiering N; Weihofen WA; Perruccio F; Calhoun A; Fazal T; Dedic D; Durand C; Dussauge S; Fettis K; Tritsch F; Dentel C; Druet A; Liu D; Kirman L; Lachal J; Namoto K; Bevan D; Mo R; Monnet G; Muller L; Zessis R; Huang X; Lindsley L; Currie T; Chiu YH; Fridrich C; Delgado P; Wang S; Hollis-Symynkywicz M; Berghausen J; Williams E; Liu H; Liang G; Kim H; Hoffmann P; Hein A; Ramage P; D'Arcy A; Harlfinger S; Renatus M; Ruedisser S; Feldman D; Elliott J; Sedrani R; Maibaum J; Adams CM
    J Med Chem; 2020 Aug; 63(15):8088-8113. PubMed ID: 32551603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design.
    Fjellström O; Akkaya S; Beisel HG; Eriksson PO; Erixon K; Gustafsson D; Jurva U; Kang D; Karis D; Knecht W; Nerme V; Nilsson I; Olsson T; Redzic A; Roth R; Sandmark J; Tigerström A; Öster L
    PLoS One; 2015; 10(1):e0113705. PubMed ID: 25629509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment.
    Lei Y; Zhang B; Zhang Y; Dai X; Duan Y; Mao Q; Gao J; Yang Y; Bao Z; Fu X; Ping K; Yan C; Mou Y; Wang S
    Eur J Med Chem; 2021 Aug; 220():113437. PubMed ID: 33894565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.
    Yang W; Wang Y; Lai A; Clark CG; Corte JR; Fang T; Gilligan PJ; Jeon Y; Pabbisetty KB; Rampulla RA; Mathur A; Kaspady M; Neithnadka PR; Arumugam A; Raju S; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Chacko SA; Bozarth JM; Wu Y; Crain EJ; Wong PC; Seiffert DA; Luettgen JM; Lam PYS; Wexler RR; Ewing WR
    J Med Chem; 2020 Jul; 63(13):7226-7242. PubMed ID: 32456431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the discovery and development of factor XI/XIa inhibitors.
    Al-Horani RA; Afosah DK
    Med Res Rev; 2018 Sep; 38(6):1974-2023. PubMed ID: 29727017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.
    Pinto DJ; Smallheer JM; Corte JR; Austin EJ; Wang C; Fang T; Smith LM; Rossi KA; Rendina AR; Bozarth JM; Zhang G; Wei A; Ramamurthy V; Sheriff S; Myers JE; Morin PE; Luettgen JM; Seiffert DA; Quan ML; Wexler RR
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1635-42. PubMed ID: 25728130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.
    Fang T; Corte JR; Gilligan PJ; Jeon Y; Osuna H; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Wexler RR; Lam PYS
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126949. PubMed ID: 31932224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.
    Corte JR; Pinto DJP; Fang T; Osuna H; Yang W; Wang Y; Lai A; Clark CG; Sun JH; Rampulla R; Mathur A; Kaspady M; Neithnadka PR; Li YC; Rossi KA; Myers JE; Sheriff S; Lou Z; Harper TW; Huang C; Zheng JJ; Bozarth JM; Wu Y; Wong PC; Crain EJ; Seiffert DA; Luettgen JM; Lam PYS; Wexler RR; Ewing WR
    J Med Chem; 2020 Jan; 63(2):784-803. PubMed ID: 31833761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.
    Dilger AK; Pabbisetty KB; Corte JR; De Lucca I; Fang T; Yang W; Pinto DJP; Wang Y; Zhu Y; Mathur A; Li J; Hou X; Smith D; Sun D; Zhang H; Krishnananthan S; Wu DR; Myers JE; Sheriff S; Rossi KA; Chacko S; Zheng JJ; Galella MA; Ziemba T; Dierks EA; Bozarth JM; Wu Y; Crain E; Wong PC; Luettgen JM; Wexler RR; Ewing WR
    J Med Chem; 2022 Feb; 65(3):1770-1785. PubMed ID: 34494428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural role of Gly(193) in serine proteases: investigations of a G555E (GLY193 in chymotrypsin) mutant of blood coagulation factor XI.
    Schmidt AE; Ogawa T; Gailani D; Bajaj SP
    J Biol Chem; 2004 Jul; 279(28):29485-92. PubMed ID: 15090552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel phenylalanine derived diamides as Factor XIa inhibitors.
    Smith LM; Orwat MJ; Hu Z; Han W; Wang C; Rossi KA; Gilligan PJ; Pabbisetty KB; Osuna H; Corte JR; Rendina AR; Luettgen JM; Wong PC; Narayanan R; Harper TW; Bozarth JM; Crain EJ; Wei A; Ramamurthy V; Morin PE; Xin B; Zheng J; Seiffert DA; Quan ML; Lam PYS; Wexler RR; Pinto DJP
    Bioorg Med Chem Lett; 2016 Jan; 26(2):472-478. PubMed ID: 26704266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of basic amino acids in the autolysis loop of factor XIa to serpin specificity.
    Rezaie AR; Sun MF; Gailani D
    Biochemistry; 2006 Aug; 45(31):9427-33. PubMed ID: 16878977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional role of residue 193 (chymotrypsin numbering) in serine proteases: influence of side chain length and beta-branching on the catalytic activity of blood coagulation factor XIa.
    Schmidt AE; Sun MF; Ogawa T; Bajaj SP; Gailani D
    Biochemistry; 2008 Feb; 47(5):1326-35. PubMed ID: 18186617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).
    Pinto DJP; Orwat MJ; Smith LM; Quan ML; Lam PYS; Rossi KA; Apedo A; Bozarth JM; Wu Y; Zheng JJ; Xin B; Toussaint N; Stetsko P; Gudmundsson O; Maxwell B; Crain EJ; Wong PC; Lou Z; Harper TW; Chacko SA; Myers JE; Sheriff S; Zhang H; Hou X; Mathur A; Seiffert DA; Wexler RR; Luettgen JM; Ewing WR
    J Med Chem; 2017 Dec; 60(23):9703-9723. PubMed ID: 29077405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of novel proline based factor XIa selective inhibitors as leads for potential new anticoagulants.
    Hussain Z; Cooke AJ; Neelamkavil S; Brown L; Carswell E; Geissler WM; Guo Z; Hawes B; Kelly TM; Kiyoi Y; Lai K; Lesburg C; Pow E; Zang Y; Wood HB; Edmondson SD; Liu W
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127072. PubMed ID: 32340773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.
    Corte JR; Fang T; Pinto DJ; Orwat MJ; Rendina AR; Luettgen JM; Rossi KA; Wei A; Ramamurthy V; Myers JE; Sheriff S; Narayanan R; Harper TW; Zheng JJ; Li YX; Seiffert DA; Wexler RR; Quan ML
    Bioorg Med Chem; 2016 May; 24(10):2257-72. PubMed ID: 27073051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrocyclic factor XIa inhibitors.
    Wang C; Corte JR; Rossi KA; Bozarth JM; Wu Y; Sheriff S; Myers JE; Luettgen JM; Seiffert DA; Wexler RR; Quan ML
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4056-4060. PubMed ID: 28780160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.
    Corte JR; Fang T; Osuna H; Pinto DJ; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Decicco CP; Wexler RR; Quan ML
    J Med Chem; 2017 Feb; 60(3):1060-1075. PubMed ID: 28085275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.
    Xue T; Ding S; Guo B; Zhou Y; Sun P; Wang H; Chu W; Gong G; Wang Y; Chen X; Yang Y
    J Med Chem; 2014 Sep; 57(18):7770-91. PubMed ID: 25179681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.